BioAtla Competitors

Sana Biotechnology (NASDAQ:SANA) and BioAtla (NASDAQ:BCAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Valuation & Earnings

This table compares Sana Biotechnology and BioAtla's top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of current ratings for Sana Biotechnology and BioAtla, as reported by MarketBeat.

BioAtla has a consensus price target of $48.00, indicating a potential downside of 9.60%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Sana Biotechnology.

Profitability

This table compares Sana Biotechnology and BioAtla's net margins, return on equity and return on assets.

Summary

BioAtla beats Sana Biotechnology on 2 of the 2 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and BioAtla (NASDAQ:BCAB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Abcam and BioAtla, as reported by MarketBeat.

Abcam currently has a consensus target price of $22.3333, suggesting a potential downside of 6.28%. BioAtla has a consensus target price of $48.00, suggesting a potential downside of 9.60%. Given Abcam's higher possible upside, analysts plainly believe Abcam is more favorable than BioAtla.

Profitability

This table compares Abcam and BioAtla's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Abcam and BioAtla's revenue, earnings per share and valuation.

Summary

BioAtla beats Abcam on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Seer (NASDAQ:SEER) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Earnings and Valuation

This table compares BioAtla and Seer's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares BioAtla and Seer's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for BioAtla and Seer, as reported by MarketBeat.

BioAtla currently has a consensus target price of $48.00, suggesting a potential downside of 9.60%. Seer has a consensus target price of $69.6667, suggesting a potential upside of 44.45%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than BioAtla.

Summary

BioAtla beats Seer on 2 of the 3 factors compared between the two stocks.

Cullinan Management (NASDAQ:CGEM) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cullinan Management and BioAtla, as provided by MarketBeat.com.

Cullinan Management currently has a consensus price target of $48.00, suggesting a potential upside of 18.75%. BioAtla has a consensus price target of $48.00, suggesting a potential downside of 9.60%. Given Cullinan Management's higher probable upside, equities analysts clearly believe Cullinan Management is more favorable than BioAtla.

Earnings & Valuation

This table compares Cullinan Management and BioAtla's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Cullinan Management and BioAtla's net margins, return on equity and return on assets.

Summary

BioAtla beats Cullinan Management on 2 of the 3 factors compared between the two stocks.

Vor Biopharma (NYSE:VOR) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.

Valuation & Earnings

This table compares Vor Biopharma and BioAtla's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Vor Biopharma and BioAtla, as reported by MarketBeat.com.

BioAtla has a consensus price target of $48.00, indicating a potential downside of 9.60%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Vor Biopharma.

Profitability

This table compares Vor Biopharma and BioAtla's net margins, return on equity and return on assets.

Summary

BioAtla beats Vor Biopharma on 2 of the 2 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Profitability

This table compares BioAtla and Silverback Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for BioAtla and Silverback Therapeutics, as provided by MarketBeat.com.

BioAtla currently has a consensus price target of $48.00, suggesting a potential downside of 9.60%. Silverback Therapeutics has a consensus price target of $46.25, suggesting a potential downside of 3.77%. Given Silverback Therapeutics' higher possible upside, analysts clearly believe Silverback Therapeutics is more favorable than BioAtla.

Valuation and Earnings

This table compares BioAtla and Silverback Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Silverback Therapeutics beats BioAtla on 1 of the 1 factors compared between the two stocks.